Lisa Christ
Lisa is a physician and clinical scientist at the Department of Rheumatology and Immunology, Inselspital, University Hospital, in Bern, Switzerland with research interests focusing on vasculitis, specifically giant cell arteritis, and Sjögren’s disease. She conducted the GUSTO trial, a proof-of-concept study in giant cell arteritis. Lisa is a founding member of the Vasculitis Association Switzerland (VASAS) and in the scientific commission of the Swiss Clinical Quality Management in Rheumatic Diseases Foundation (SCQM). She is a member of the EMEUNET Peer Mentoring Sub-Committee.
| ORAL 1765 | Tuesday, 28.10.2025 10:15 Abstract Session: Vasculitis – ANCA-Associated Presenting author: Puéchal, X (France) Title: Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial  This interesting study compared rituximab versus azathioprine in EGPA and found no overall superiority of rituximab to azathioprine in maintaining vasculitis remission, reducing asthma/rhinosinusitis exacerbations or sparing GC. |
| Poster 1603 | Monday, 27.10.25 10:30 Abstract Session: Vasculitis – ANCA-Associated Poster II Presenting author: Foos, J (USA) Title: SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement This interesting retrospective cohort study assessed the effects of SGLT-2 inhibitors on renal-related outcome measures in patients with ANCA-associated vasculitis and type 2 diabetes and found a lower risk of ESRD and kidney transplant infection and lower 5-year mortality in SGLT-2i users. |
| Poster 1601 | Monday, 27.10.25 10:30 Abstract Session: Vasculitis – ANCA-Associated Poster II Presenting author: Au, H (Germany) Title: Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series This interesting case series reports that obinutuzumab was effective and well tolerated in five patients who received obinutuzumab therapy for refractory or relapsing PR3+ granulomatosis with polyangiitis. |
| Oral 2699 | Wednesday, 29.10.25 11:30 Abstract Session: Vasculitis – Non-ANCA-Associated & Related Disorders II Presenting author: Mariotti, E (Italy) Title: Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study This interesting retrospective study identified 407 patients with cutaneous IgA vasculitis treated with colchicine, dapsone, or GCs. It found that GCs were associated with a more favorable outcome than colchicine in achieving sustained remission of cutaneous involvement. |
| Oral 0891 | Monday, 27.10.25 10:00 Abstract Session: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside Presenting author: Samson, M (France) Title: MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial This interesting open-label study compared methotrexate versus tocilizumab in patients with GCA and found – with a non-inferiority margin of 20%– that MTX was non-inferior to TCZ regarding the primary endpoint (percentage of patients alive, without relapse after initial remission or deviation from the GC taper regimen from inclusion to W78). |
| Oral 0776 | Sunday, 26.10.25 10:45 Abstract Session: Plenary I Presenting author: Schmidt, W (Germany) Title: Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial This interesting study reports the 2-year outcomes of the SELECT-GCA trial: 68.6% of patients on continuous UPA15 maintained remission vs 28.6% who switched from UPA15 to placebo. |